These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37657455)

  • 21. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.
    Boisseau W; Euskirchen P; Mokhtari K; Dehais C; Touat M; Hoang-Xuan K; Sanson M; Capelle L; Nouet A; Karachi C; Bielle F; Guégan J; Marie Y; Martin-Duverneuil N; Taillandier L; Rousseau A; Delattre JY; Idbaih A
    Oncologist; 2019 Dec; 24(12):1584-1592. PubMed ID: 31346129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.
    Russo A; Incorvaia L; Malapelle U; Del Re M; Capoluongo E; Vincenzi B; Chiari R; Cortesi L; Danesi R; Florena AM; Fontanini G; Gori S; Marchetti A; Normanno N; Pinto C; Sangiolo D; Silvestris N; Tagliaferri P; Tallini G; Cinieri S; Beretta GD
    Crit Rev Oncol Hematol; 2021 Sep; 165():103436. PubMed ID: 34371157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
    Chakravarty D; Johnson A; Sklar J; Lindeman NI; Moore K; Ganesan S; Lovly CM; Perlmutter J; Gray SW; Hwang J; Lieu C; André F; Azad N; Borad M; Tafe L; Messersmith H; Robson M; Meric-Bernstam F
    J Clin Oncol; 2022 Apr; 40(11):1231-1258. PubMed ID: 35175857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy.
    Vranic S; Gatalica Z
    Biomol Biomed; 2024 Apr; ():. PubMed ID: 38656302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
    Baretti M; Azad NS
    Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
    Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
    World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of tissue-agnostic approvals for patients with sarcoma.
    Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
    Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
    Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
    Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial cancer: Molecular markers and management of advanced stage disease.
    Arend RC; Jones BA; Martinez A; Goodfellow P
    Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies.
    Marchetti A; Ferro B; Pasciuto MP; Zampacorta C; Buttitta F; D'Angelo E
    Pathologica; 2022 Jun; 114(3):199-216. PubMed ID: 35775706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.
    Wang J; Yi Y; Xiao Y; Dong L; Liang L; Teng L; Ying JM; Lu T; Liu Y; Guan Y; Pang J; Zhou L; Lu J; Zhang Z; Liu X; Liang X; Zeng X; Yi X; Zhou W; Xia X; Yang L; Zhang J; Kopetz S; Futreal PA; Wu H; Liang Z
    Mod Pathol; 2019 Jul; 32(7):1053-1064. PubMed ID: 30723297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.